Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 25, 2024 09:41 ET | Source: ADvantage Therapeutics, Inc.

Advantage Therapeutics Inc. Announces Formation of Klothea Bio, Inc. to Advance Research and Development of Klotho Protein for Age-Related Therapeutics

MIAMI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Advantage Therapeutics Inc., a leader in developing therapies targeting age-related diseases, announced today the formation of its new subsidiary, Klothea...
September 09, 2024 10:01 ET | Source: ADvantage Therapeutics, Inc.

ADvantage Therapeutics, Inc. Welcomes Dr. William A. Haseltine as Strategic Advisor to Drive Innovation in Alzheimer's Disease Research and Anti-aging Therapies such as Klotho Protein Supplementation to Extend Healthy Human Lifespan

MIAMI, Sept. 09, 2024 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc., a leading clinical-stage biotechnology company dedicated to the advancement of innovative therapies for Alzheimer's disease,...
April 09, 2024 08:00 ET | Source: Creyos

Creyos Health Announces Addition of Dementia Screening, Testing, and Care Planning to its Online Platform

Toronto, Canada, April 09, 2024 (GLOBE NEWSWIRE) -- Creyos Health, a pioneering healthcare technology company dedicated to objective brain health measurement, has unveiled an end-to-end online...
March 05, 2024 08:00 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease

BETHESDA, Md., March 05, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of...
November 27, 2023 08:45 ET | Source: Advantage Therapeutics Inc.

ADvantage Therapeutics Has Commenced Enrollment for Its Phase 2b Clinical Trial of AD04™ for Treatment of Alzheimer’s Disease

MIAMI, Nov. 27, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), a pioneer in developing therapies for neurodegenerative conditions by addressing the biology of...
November 14, 2023 07:00 ET | Source: Amydis, Inc.

Amydis Receives $3.4 million NIH Commercialization Readiness Pilot Grant Award to Map Heterogeneity of Alzheimer’s Diseases in Human Clinical Trial Using Novel Retinal Tracer

Amydis Receives $3.4 million NIH Grant Award to Map Heterogeneity of Alzheimer’s in Human Clinical Trial Using Novel Retinal Tracer
November 02, 2023 07:00 ET | Source: Amydis, Inc.

Amydis Launches Phase 2 Glaucoma Clinical Program Using Novel Retinal Tracer to Detect Amyloid Beta

Amydis announces Phase 2 clinical program for its novel retinal tracer, AMDX-2011P, to detect amyloid-beta in glaucoma patients.
June 20, 2023 09:00 ET | Source: Advantage Therapeutics Inc.

ADvantage Therapeutics Secures Approvals for Clinical Trial of AD04™ in Alzheimer’s Disease Treatment in Poland, Bulgaria, and Slovakia

MIAMI, June 20, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), a pioneer in developing therapies for neurodegenerative conditions with a focus on Alzheimer’s...